Trial Profile
Glucagon-Like Peptide-1 Agonist Effects on Energy Balance in Hypothalamic Obesity
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 17 May 2022
Price :
$35
*
At a glance
- Drugs Exenatide (Primary)
- Indications Obesity
- Focus Therapeutic Use
- Acronyms ECHO
- 01 Jul 2021 Results assessing whether neuroimaging-delineated regions of hypothalamic injury are associated with a differential treatment response to a glucagon-like peptide-1 receptor agonist (GLP-1RA) in patients with hypothalamic obesity published in the Diabetes, Obesity and Metabolism
- 19 Aug 2020 Status changed from active, no longer recruiting to completed.
- 02 Apr 2019 Planned End Date changed from 1 Dec 2019 to 1 Mar 2020.